These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28267392)

  • 1. Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated With Aromatase Inhibitors.
    Stratton J; Hu X; Soulos PR; Davidoff AJ; Pusztai L; Gross CP; Mougalian SS
    J Oncol Pract; 2017 May; 13(5):e505-e515. PubMed ID: 28267392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of bone mineral density screening on incident fractures and healthcare resource utilization among postmenopausal breast cancer survivors treated with aromatase inhibitors.
    Bailey S; Mhango G; Lin JJ
    Osteoporos Int; 2022 Sep; 33(9):1989-1997. PubMed ID: 35697870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone Mineral Density at the Time of Initiating Aromatase Inhibitor Therapy Is Associated With Decreased Fractures in Women With Breast Cancer.
    Lu H; Lei X; Zhao H; Elting L; Siricilla M; Ursani MA; Giordano SH; Suarez-Almazor M
    J Bone Miner Res; 2021 May; 36(5):861-871. PubMed ID: 33484602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of osteoporosis as a consequence of aromatase inhibitor therapy in postmenopausal women with early breast cancer: rationale and design of a randomized controlled trial.
    Kilbreath S; Refshauge KM; Beith J; Ward L; Sawkins K; Paterson R; Clifton-Bligh P; Sambrook PN; Simpson JM; Nery L
    Contemp Clin Trials; 2011 Sep; 32(5):704-9. PubMed ID: 21570487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy.
    Pedersini R; Amoroso V; Maffezzoni F; Gallo F; Turla A; Monteverdi S; Ardine M; Ravanelli M; Vassalli L; Rodella F; Formenti AM; Dalla Volta A; Simoncini EL; Giustina A; Maroldi R; Berruti A
    JAMA Netw Open; 2019 Sep; 2(9):e1911080. PubMed ID: 31560383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
    Gnant M; Pfeiler G; Dubsky PC; Hubalek M; Greil R; Jakesz R; Wette V; Balic M; Haslbauer F; Melbinger E; Bjelic-Radisic V; Artner-Matuschek S; Fitzal F; Marth C; Sevelda P; Mlineritsch B; Steger GG; Manfreda D; Exner R; Egle D; Bergh J; Kainberger F; Talbot S; Warner D; Fesl C; Singer CF;
    Lancet; 2015 Aug; 386(9992):433-43. PubMed ID: 26040499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of dual-energy X-ray absorptiometry plus antiresorptive treatment in Australian women with breast cancer who receive aromatase inhibitors.
    Sowa PM; Downes MJ; Gordon LG
    J Bone Miner Metab; 2017 Mar; 35(2):199-208. PubMed ID: 26969395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
    Hong AR; Kim JH; Lee KH; Kim TY; Im SA; Kim TY; Moon HG; Han WS; Noh DY; Kim SW; Shin CS
    Osteoporos Int; 2017 Apr; 28(4):1413-1422. PubMed ID: 28083668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy.
    Dieckmeyer M; Ruschke S; Rohrmeier A; Syväri J; Einspieler I; Seifert-Klauss V; Schmidmayr M; Metz S; Kirschke JS; Rummeny EJ; Zimmer C; Karampinos DC; Baum T
    BMC Musculoskelet Disord; 2019 Nov; 20(1):515. PubMed ID: 31694630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative ultrasound and DXA measurements in aromatase inhibitor-treated breast cancer women receiving denosumab.
    Catalano A; Gaudio A; Morabito N; Basile G; Agostino RM; Xourafa A; Atteritano M; Morini E; Natale G; Lasco A
    J Endocrinol Invest; 2017 Aug; 40(8):851-857. PubMed ID: 28332172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
    Nogues X; Servitja S; Peña MJ; Prieto-Alhambra D; Nadal R; Mellibovsky L; Albanell J; Diez-Perez A; Tusquets I
    Maturitas; 2010 Jul; 66(3):291-7. PubMed ID: 20399042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone Mineral Density Testing Disparities Among Patients With Breast Cancer Prescribed Aromatase Inhibitors.
    Charlson J; Smith EC; Smallwood AJ; Laud PW; Neuner JM
    J Natl Compr Canc Netw; 2016 Jul; 14(7):875-80. PubMed ID: 27407128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
    Gibson K; O'Bryant CL
    J Oncol Pharm Pract; 2008 Sep; 14(3):139-45. PubMed ID: 18719068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging bone health issues in women with breast cancer in Hawai'i.
    Carney JF; Davis J
    Hawaii Med J; 2007 Jun; 66(6):164-6. PubMed ID: 17621865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer.
    Becker T; Lipscombe L; Narod S; Simmons C; Anderson GM; Rochon PA
    J Am Geriatr Soc; 2012 Sep; 60(9):1761-7. PubMed ID: 22985145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study.
    Pedersini R; Monteverdi S; Mazziotti G; Amoroso V; Roca E; Maffezzoni F; Vassalli L; Rodella F; Formenti AM; Frara S; Maroldi R; Berruti A; Simoncini E; Giustina A
    Bone; 2017 Apr; 97():147-152. PubMed ID: 28104509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy.
    Kwan ML; Yao S; Laurent CA; Roh JM; Quesenberry CP; Kushi LH; Lo JC
    Breast Cancer Res Treat; 2018 Apr; 168(2):523-530. PubMed ID: 29249058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for osteoporosis after breast cancer: for whom, why and when.
    Trémollieres FA
    Maturitas; 2014 Nov; 79(3):343-8. PubMed ID: 25308162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
    Yonehara Y; Iwamoto I; Kosha S; Rai Y; Sagara Y; Douchi T
    J Obstet Gynaecol Res; 2007 Oct; 33(5):696-9. PubMed ID: 17845332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.